Evaluation of Retinal and Vascular Features in Radiation Maculopathy After Intravitreal Injections of Ranibizumab
- Sponsor
- Federico II University
- Study ID
- NCT04377295
- Status
- Completed
Conditions
- Radiation Maculopathy
Eligibility Criteria
- Sex
- ALL
- Age
- 40 Years - 60 Years
- Healthy Volunteers
- Not accepted
Interventions
- Ranibizumab 0.5Mg/0.05Ml Oph Inj — DRUGAll patients received one monthly intravitreal injection of Ranibizumab (0.5 mg/0.05 ml) through the pars plana under aseptic conditions until maximum visual acuity was achieved and there was no sign of macular edema at optical coherence tomography
Study Details
This study evaluates the retinal and vascular features in patients with radiation maculopathy under the effects of Ranibizumab intravitreal injections using optical coherence tomography and optical coherence tomography angiography.
Key Dates
- First listed
- May 6, 2020
- Start date
- Oct 30, 2012
- Status verified
- May 2020
- Primary completion
- Oct 1, 2019
- Completion
- Oct 30, 2019
Study Design
- Enrollment
- 40 participants (actual)
Primary Outcome Measure
Study of retinal and vascular features in pazients affected by radiation maculopathy after intravitreal injections of Ranibizumab [ Time Frame: one year ]